AMGN vs GSK
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Jul 27, 2026
AMGN
51.2
AI Score
VS
AMGN Wins
GSK
44.3
AI Score
Investment Advisor Scores
GSK
44score
Recommendation
HOLD
AI Analyst Insights
AI insights temporarily unavailable
Detailed Metrics Comparison
| Metric | AMGN | GSK | Winner |
|---|
Relative Price Performance (Last 90 Days)
AMGN 1M: +1.3%
· 3M: +14.9%
GSK 1M: -4.0%
· 3M: -0.2%
Current Technical Phase
AMGN
MarkupHold / add on dips
Price above SMA50, rising 50-day trend (4.4% over 20 days), RSI 58
GSK
DistributionTrim / tighten stop
Price near a flattening SMA50 (slope 0.3%) with fading momentum, RSI 48
Fundamentals Snapshot
| Metric | AMGN | GSK |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 16.2 | 10.0 |
| Trailing P/E | 26.8 | 16.4 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.1% | 0.1% |
| Gross Margin | 0.7% | 0.7% |
| Operating Margin | 0.3% | 0.3% |
| EPS | 14.37 | 3.15 |
| Dividend Yield | 0.02% | 0.04% |
Frequently Asked Questions
Based on our detailed analysis, AMGN is currently the stronger investment candidate based on our comprehensive scoring model.
We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.
Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.